Lyne Paré

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.

Haemacure Corp. is engaged in the development, marketing and sales of surgical sealants and related medical devices. Its primary product is a fibrin sealant, a tissue sealant comprised of fibrinogen and thrombin extracted from human plasma. The fibrin sealant is used in surgical procedures to arrest bleeding and as an adjunct to wound healing. It was founded on August 19, 1991 and is headquartered in Montreal, Canada.